Clinical Trial Update: Exploratory and Safety Study of [F-18]W372 [EARLY_Phase 1]

View source ↗

Summary

Siemens Molecular Imaging completed an exploratory and safety Phase 1 study of the PET tracer [F-18]W372 for Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [F-18]W372 (Fluorine-18 labeled imaging radiotracer W372)

Snippet

Sponsor: Siemens Molecular Imaging | Conditions: Alzheimer's Disease | EARLY_Phase 1 | Status: COMPLETED